SCHEMBL21952095

SCHEMBL21952095

O=C(O)c1ccc(-n2nnnc2SCC(=O)c2ccc(C(F)(F)F)cc2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 6/20 0.64
▸ HPGD P15428 3/20 0.58
▸ MEN1 O00255 7/20 0.57
▸ KMT2A Q03164 7/20 0.57
▸ ALDH1A1 P00352 6/20 0.57
▸ POLB P06746 5/20 0.57
▸ ALPL P05186 4/20 0.57
▸ ALPG P10696 4/20 0.57
▸ LMNA P02545 4/20 0.57
▸ KDM4E B2RXH2 3/20 0.57
▸ GAA P10253 3/20 0.57
▸ RECQL P46063 3/20 0.57
▸ SMN1; SMN2 Q16637 3/20 0.57
▸ JAK2 O60674 2/20 0.57
▸ USP2 O75604 2/20 0.57
▸ TSHR P16473 3/20 0.56
▸ MAPK1 P28482 2/20 0.55
▸ L3MBTL1 Q9Y468 3/20 0.54
▸ THRB P10828 1/20 0.54
▸ APEX1 P27695 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21951986 0.91 MAPT (0.71) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL24019794 0.89 MAPT (0.61) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL24209668 0.89 MAPT (0.60) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL24209657 0.87 MAPT (0.82) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL21952054 0.87 MAPT (0.64) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL24209682 0.87 MAPT (0.71) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL30620388 0.86 ALPG (0.78) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL27303528 0.86 ALPG (0.78) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL21952082 0.85 MAPT (0.64) MAPTHPGDMEN1KMT2AALDH1A1
SCHEMBL24209661 0.85 MAPT (0.64) MAPTHPGDMEN1KMT2AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3880199-B1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS FUNDACION PUBLICA GALLEGA DE INVESTIG BIOMEDICA INIBIC (ES) 2025-04-23 — — EP disclosed
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 — — US disclosed
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 — — US disclosed
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER FUND PROFESOR NOVOA SANTOS (ES) 2023-06-15 — — US disclosed
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS FUND PROFESOR NOVOA SANTOS (ES) 2022-01-20 — — US disclosed
EP-3909577-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER Fundación Profesor Novoa Santos (ES) 2021-11-17 — — EP disclosed
EP-3653208-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS Fundación Profesor Novoa Santos (ES) 2020-05-20 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230181535-A1 UBIQUITIN-LIGASE INHIBITORS FOR THE TREATMENT OF CANCER XIAP, UBQLN1, MDM2 MAPT 1710/4885HPGD 2761/4885MEN1 3372/4885
US-20220016080-A1 COMPOUNDS THAT SELECTIVELY AND EFFECTIVELY INHIBIT HAKAI-MEDIATED UBIQUITINATION, AS ANTI-CANCER DRUGS CHUK, HIPK3, HIPK1 MAPT 3296/4885HPGD 1570/4885MEN1 3702/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback